Tirzepatide emerges a groundbreaking therapeutic agent for individuals facing type 2 diabetes. As a dual agonist, it targets both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide https://barryvhlw724241.luwebs.com/41410646/tirzepatide-a-novel-glp-1-and-gip-receptor-agonist